A numerical imbalance of preterm births in people who received Pfizer Inc.’s respiratory syncytial virus vaccine while pregnant in clinical trials is likely to be the key focus of the immunization’s 18 May Vaccines and Related Biological Products Advisory Committee meeting.
Pfizer is seeking approval for Abrysvo (RSVpreF) to prevent lower respiratory tract disease and severe lower respiratory tract disease caused by RSV in infants from birth through six
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?